NASDAQ:RXRX | Free Cash Flow | RECURSION PHARMACEUTICALS, INC.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$81.1M$258,000.00-$81.36M
2025-12-31-$46.07M$1.24M-$47.32M
2025-03-31-$131.96M$1.83M-$133.79M
2024-12-31-$115.43M$1.3M-$116.73M
2024-03-31-$102.3M$6.65M-$108.95M
2023-12-31-$74.08M$2.07M-$76.14M
2023-03-31-$73.32M$5.18M-$78.49M
2022-12-31-$44.75M$7.98M-$52.73M
2022-03-31$77.39M$4.34M$73.05M
2021-12-31-$61.16M$4.46M-$65.62M
2021-03-31-$30.76M$19.42M-$50.17M
2020-12-31$8.57M$3.69M$4.89M
2020-03-31-$17.82M$684,000.00-$18.5M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$371.81M$6.47M-$378.28M
2024-12-31-$359.17M$13.7M-$372.87M
2023-12-31-$287.78M$11.96M-$299.74M
2022-12-31-$83.52M$37.06M-$120.58M
2021-12-31-$158.61M$39.8M-$198.41M
2020-12-31-$45.4M$5.83M-$51.23M
2019-12-31-$57.04M$3.91M-$60.95M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.